TO BE PUBLISHED March 2022
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
It will be an opportunity to discuss the role of NICE in a changing health and social care landscape following the pandemic.
Delegates will also examine proposals in the NICE Strategy 2021 to 2026: Dynamic, Collaborative, Excellent, which sets out a vision and priorities for transformation to keep pace with the development of integrated care, innovative treatments, and data-driven research and technology.
We are pleased to be able to include an opening keynote session with a senior speaker confirmed from NICE, as well as a contribution from Dr Paul Chrisp, Director, Centre for Guidelines, NICE.
There will also be keynote contributions from: Dr Ben Goldacre, Lead, Goldacre Review; and Director, The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; Paul Naish, Head of UK Policy, AstraZeneca; Luella Trickett, Director, Value and Access, Association of British Healthcare Industries; David Thomas, Head of Policy for Access and Innovation, Alzheimer’s Research UK; Professor Matt Westmore, Chief Executive, Health Research Authority.
Overall, the agenda will bring out latest thinking on:
- what is needed to deliver the ambitions set out in the NICE Strategy 2021 to 2026
- adapting recommendations and developing evidence-based guidelines in a changing health and care landscape
- priorities for utilising data and its role in developing guidance and centring on the needs of the patient
- opportunities for developing and adopting innovative medicines and health technology
- what is needed to support patient access to innovation, including the role of managed access and funding
The discussion is bringing together stakeholders with key policy officials who are due to attend from the DHSC; the MHRA; the Office for Life Sciences; BEIS; DCMS; DIT; The Scottish Government; and the Welsh Government.